Previous 10 | Next 10 |
home / stock / sage / sage articles
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday. Shares of Mama’s Creations Inc (...
Sage Therapeutics, Inc. (NASDAQ:SAGE) shares are trading lower on Tuesday. The company eelier announced results from its Phase 2 Huntington’s...
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or th...
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or ...
U.S. stock futures were lower this morning, with the Nasdaq futures declining over 100 points on Friday. Shares of Netflix, Inc. (NASDAQ:NFLX) fell...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to...
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers repo...
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.32% to 37,6...
Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in pe...
News, Short Squeeze, Breakout and More Instantly...
Sage Therapeutics Inc. Company Name:
SAGE Stock Symbol:
NASDAQ Market:
Sage Therapeutics Inc. Website:
2024-06-20 13:15:04 ET Scotiabank analyst issues UNDERPERFORM recommendation for SAGE on June 20, 2024 10:00AM ET. The previous analyst recommendation was Underperform. SAGE was trading at $10.525 at issue of the analyst recommendation. The overall analyst consensus : HO...
2024-06-20 13:15:04 ET Wedbush analyst issues SECTOR PERFORM recommendation for SAGE on June 20, 2024 10:00AM ET. The previous analyst recommendation was Sector Perform. SAGE was trading at $10.525 at issue of the analyst recommendation. The overall analyst consensus : H...
The SURVEYOR Study met its primary endpoint demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery ( HD-CAB) composite score at baseline between healthy participants and participants with Huntington’s Disease (HD) prior to any treatment ...